应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
06978 永泰生物-B
休市中 05-09 16:08:07
3.580
-0.110
-2.98%
最高
3.790
最低
3.500
成交量
31.50万
今开
3.560
昨收
3.690
日振幅
7.86%
总市值
18.42亿
流通市值
18.42亿
总股本
5.15亿
成交额
111.28万
换手率
0.06%
流通股本
5.15亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）
资讯
新帖
简况
福安药业：公司药品研发目前以仿制药为主暂无具体创新药规划
证券之星 · 05-09 08:03
福安药业：公司药品研发目前以仿制药为主暂无具体创新药规划
永泰生物-B盘中异动 临近收盘大幅跳水5.15%
市场透视 · 05-09 07:57
永泰生物-B盘中异动 临近收盘大幅跳水5.15%
【券商聚焦】兴业证券上调翰森制药(03692)至“买入”评级 指其核心商业化创新药品种保持快速增长
金吾财讯 · 05-09 07:32
【券商聚焦】兴业证券上调翰森制药(03692)至“买入”评级 指其核心商业化创新药品种保持快速增长
国泰海通证券：创新药高景气 多细分板块迎拐点
财中社 · 05-09 06:43
国泰海通证券：创新药高景气 多细分板块迎拐点
ETF两市成交额770.42亿元
美港电讯 · 05-09 02:36
ETF两市成交额770.42亿元
港股创新药ETF涨超1.4%，三生制药涨超5%，机构：2025年国内创新药产业有望迎来拐点
21世纪经济报道 · 05-09 01:59
港股创新药ETF涨超1.4%，三生制药涨超5%，机构：2025年国内创新药产业有望迎来拐点
A股创新药概念板块异动拉升，舒泰神涨超10%，海创药业涨超6%，热景生物、恒瑞医药、通化金马跟涨。
美港电讯 · 05-09 01:40
A股创新药概念板块异动拉升，舒泰神涨超10%，海创药业涨超6%，热景生物、恒瑞医药、通化金马跟涨。
英硅智能冲刺“港股AI创新药第一股”：拥有全球进展最快的AI驱动研发项目
IPO早知道 · 05-09 01:40
英硅智能冲刺“港股AI创新药第一股”：拥有全球进展最快的AI驱动研发项目
健康元：目前公司已上市的创新药占整体业绩比例较小，因此暂未单独详细披露
证券之星 · 05-08 10:27
健康元：目前公司已上市的创新药占整体业绩比例较小，因此暂未单独详细披露
健康元：目前在吸入制剂板块中仅有妥布霉素吸入溶液这一创新药品种
证券之星 · 05-08 10:21
健康元：目前在吸入制剂板块中仅有妥布霉素吸入溶液这一创新药品种
健康元：仿制药业务受集采政策影响，创新药管线处于研发阶段
证券之星 · 05-08 10:21
健康元：仿制药业务受集采政策影响，创新药管线处于研发阶段
总投资4.75亿美元 阿斯利康无锡小分子药物新工厂正式开工
美港电讯 · 05-08 10:13
总投资4.75亿美元 阿斯利康无锡小分子药物新工厂正式开工
永泰生物-B05月08日主力净流出28.8万元 散户资金买入
市场透视 · 05-08 08:15
永泰生物-B05月08日主力净流出28.8万元 散户资金买入
永泰生物-B盘中异动 大幅上涨5.05%报3.950港元
市场透视 · 05-08 01:36
永泰生物-B盘中异动 大幅上涨5.05%报3.950港元
涉及减肥药？股价盘中多次触及涨停 常山药业回应：艾本那肽无最新进展
美港电讯 · 05-07 07:16
涉及减肥药？股价盘中多次触及涨停 常山药业回应：艾本那肽无最新进展
创新药概念持续调整 百济神州跌7.31% 机构指医药板块中最值得关注的仍是创新药赛道
金吾资讯 · 05-07 06:03
创新药概念持续调整 百济神州跌7.31% 机构指医药板块中最值得关注的仍是创新药赛道
A股创新药概念午后持续下挫，百济神州跌近9%，荣昌生物、益方生物、一品红、信立泰、迪哲医药等多股跌超5%。
美港电讯 · 05-07 05:56
A股创新药概念午后持续下挫，百济神州跌近9%，荣昌生物、益方生物、一品红、信立泰、迪哲医药等多股跌超5%。
【创新药概念持续调整 百济神州跌近9%】午后创新药概念持续下挫，百济神州跌近9%，荣昌生物、益方生物、一品红、信立泰、迪哲医药等多股跌逾5%。
金融界 · 05-07 05:54
【创新药概念持续调整 百济神州跌近9%】午后创新药概念持续下挫，百济神州跌近9%，荣昌生物、益方生物、一品红、信立泰、迪哲医药等多股跌逾5%。
昌平区一季度GDP同比增长7.9%！民企助力跑赢全市增速
北京日报客户端 · 05-06
昌平区一季度GDP同比增长7.9%！民企助力跑赢全市增速
重磅!远大医药(00512)全球创新药STC3141中国II期临床数据亮剑，脓毒症治疗迎来突破性进展
智通财经 · 05-06
重磅!远大医药(00512)全球创新药STC3141中国II期临床数据亮剑，脓毒症治疗迎来突破性进展
加载更多
公司概况
公司名称：
永泰生物-B
所属市场：
SEHK
上市日期：
--
主营业务：
永泰生物制药有限公司是一家主要从事用于治疗癌症的细胞免疫产品的研发、制造及商业化业务的中国投资控股公司。其主要产品是EAL、CAR-T细胞系列及TCR-T细胞系列产品。EAL是一种多靶点细胞免疫治疗产品。它还提供细胞冻存服务。该公司主要在中国境内开展业务。
发行价格：
--
{"stockData":{"symbol":"06978","market":"HK","secType":"STK","nameCN":"永泰生物-B","latestPrice":3.58,"timestamp":1746778087020,"preClose":3.69,"halted":0,"volume":315000,"delay":0,"floatShares":514584000,"shares":514584000,"eps":-0.39023206913772324,"marketStatus":"休市中","change":-0.11,"latestTime":"05-09 16:08:07","open":3.56,"high":3.79,"low":3.5,"amount":1112800,"amplitude":0.078591,"askPrice":3.59,"askSize":8000,"bidPrice":3.5,"bidSize":4000,"shortable":0,"etf":0,"ttmEps":-0.39023206913772324,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1747013400000},"marketStatusCode":7,"adr":0,"listingDate":1594310400000,"exchange":"SEHK","adjPreClose":3.69,"openAndCloseTimeList":[[1746754200000,1746763200000],[1746766800000,1746777600000]],"volumeRatio":2.624999997375,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06978","defaultTab":"news","newsList":[{"id":"2534275821","title":"福安药业：公司药品研发目前以仿制药为主暂无具体创新药规划","url":"https://stock-news.laohu8.com/highlight/detail?id=2534275821","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534275821?lang=zh_cn&edition=full","pubTime":"2025-05-09 16:03","pubTimestamp":1746777787,"startTime":"0","endTime":"0","summary":"证券之星消息，福安药业(300194)05月09日在投资者关系平台上答复投资者关心的问题。投资者提问：为了公司长远发展，公司有没有在做好仿制药的基础上研发一到两款创新药的打算福安药业回复：您好，公司药品研发目前以仿制药为主，截止目前，公司已进入注册程序的药品研发项目暂无创新药，未来，公司将根据公司和市场实际情况，从长远发展角度，做好研发项目的选择和规划，目前暂无具体可提供的信息，谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025050900021946.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK0132","300194","BK0239","06978","BK1161","BK0028","BK0060","159992"],"gpt_icon":0},{"id":"2534273471","title":"永泰生物-B盘中异动 临近收盘大幅跳水5.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2534273471","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534273471?lang=zh_cn&edition=full","pubTime":"2025-05-09 15:57","pubTimestamp":1746777440,"startTime":"0","endTime":"0","summary":"2025年05月09日临近收盘15时57分，永泰生物-B股票出现异动，股价大幅下跌5.15%。永泰生物-B股票所在的生物技术行业中，整体跌幅为0.44%。消息层面，截至15时57分，《永泰生物-B：2024年亏损1.87亿元》资讯为影响永泰生物-B的重要信息。以4月29日收盘价计算，永泰生物-B目前市净率约-138.34倍。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050915572194f183e5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050915572194f183e5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","06978"],"gpt_icon":0},{"id":"2534973124","title":"【券商聚焦】兴业证券上调翰森制药(03692)至“买入”评级 指其核心商业化创新药品种保持快速增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2534973124","media":"金吾财讯","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534973124?lang=zh_cn&edition=full","pubTime":"2025-05-09 15:32","pubTimestamp":1746775974,"startTime":"0","endTime":"0","summary":"该行续指，公司创新药收入占比高，驱动业绩保持快速增长，自主研发以及BD双轮驱动，早期管线布局丰富，同时积极进行国际化布局，打开海外市场想象空间。对应2025年5月2日收盘价，PE分别为30.77x、27.16x、23.83x，上调至“买入”评级。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250109/NWI3NDNkNGUxZmM1MTMzOTE0MzEwMTk=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NWI3NDNkNGUxZmM1MTMzOTE0MzEwMTk=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1958413","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["601377","03692","06978","159992"],"gpt_icon":0},{"id":"2534125820","title":"国泰海通证券：创新药高景气 多细分板块迎拐点","url":"https://stock-news.laohu8.com/highlight/detail?id=2534125820","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534125820?lang=zh_cn&edition=full","pubTime":"2025-05-09 14:43","pubTimestamp":1746773015,"startTime":"0","endTime":"0","summary":"5月9日，国泰海通证券发表研究报告称，2024年及2025年第一季度医药各细分板块业绩表现分化，创新药带动制药板块景气度持续向上，多个细分板块有望迎来拐点，持续推荐创新药等主线。化学制剂企业近几年持续推进降本增效，销售费用率持续优化，盈利能力有望逐步提升。国产创新药持续放量，海外销售趋势向好。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050914443797542c19&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050914443797542c19&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1147","601211","02611","06978","BK1564","BK1161"],"gpt_icon":0},{"id":"2534112821","title":"ETF两市成交额770.42亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2534112821","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534112821?lang=zh_cn&edition=full","pubTime":"2025-05-09 10:36","pubTimestamp":1746758195,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["03033","BK1161","BK4550","159992","159740","03032","06978","FDN","BK1574","513130","BK4585","BK1610","BK4588"],"gpt_icon":0},{"id":"2534119631","title":"港股创新药ETF涨超1.4%，三生制药涨超5%，机构：2025年国内创新药产业有望迎来拐点","url":"https://stock-news.laohu8.com/highlight/detail?id=2534119631","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534119631?lang=zh_cn&edition=full","pubTime":"2025-05-09 09:59","pubTimestamp":1746755947,"startTime":"0","endTime":"0","summary":"5月9日，恒生指数高开0.35%，创新药板块持续活跃。相关ETF方面，截至发稿，港股创新药ETF高开高走，现涨1.41%。成分股中，三生制药涨超5%，再鼎医药、远大医药、君实生物、信达生物等股涨幅居前。港股创新药ETF紧密跟踪港股通创新药指数，该指数反映港股通生物科技产业上市公司的运行特征。湘财证券指出，2025年国内创新药产业有望迎来拐点，产业运行趋势由资本驱动转向盈利驱动，板块有望迎来业绩与估值双重修复投资机会。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509100415a6d86e17&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509100415a6d86e17&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1593","BK1574","06978","01530","BK1161"],"gpt_icon":0},{"id":"2534560113","title":"A股创新药概念板块异动拉升，舒泰神涨超10%，海创药业涨超6%，热景生物、恒瑞医药、通化金马跟涨。","url":"https://stock-news.laohu8.com/highlight/detail?id=2534560113","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534560113?lang=zh_cn&edition=full","pubTime":"2025-05-09 09:40","pubTimestamp":1746754831,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0196","LU2488822045.USD","LU1969619763.USD","159992","600276","BK0028","BK0188","LU1064130708.USD","BK0060","000766","399300","BK1574","LU1328615791.USD","300204","BK0077","688068","688302","BK0239","LU0405327494.USD","LU0405327148.USD","06978","BK0012","159982","BK0046","BK1161","BK0183","LU2328871848.SGD","LU2148510915.USD","LU1064131003.USD"],"gpt_icon":0},{"id":"2534142988","title":"英硅智能冲刺“港股AI创新药第一股”：拥有全球进展最快的AI驱动研发项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2534142988","media":"IPO早知道","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534142988?lang=zh_cn&edition=full","pubTime":"2025-05-09 09:40","pubTimestamp":1746754800,"startTime":"0","endTime":"0","summary":" 这意味着，英硅智能继续向“港股AI创新药第一股”发起冲击。 英硅智能在招股书中表示，IPO募集所得资金净额将主要用于为关键临床阶段管线候选药物的进一步临床研发提供资金；开发新的生成式AI模型和相关的验证研究工作；进一步开发并扩展自动化实验室；为早期药物发现及开发的研发提供资金；以及用作营运资金及其他一般企业用途。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/2025-05-09/doc-inevxvsc8756339.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4614","HSTECH","BK1574","HSCEI","YANG","06978","BK1161","159992"],"gpt_icon":1},{"id":"2533390448","title":"健康元：目前公司已上市的创新药占整体业绩比例较小，因此暂未单独详细披露","url":"https://stock-news.laohu8.com/highlight/detail?id=2533390448","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533390448?lang=zh_cn&edition=full","pubTime":"2025-05-08 18:27","pubTimestamp":1746700038,"startTime":"0","endTime":"0","summary":"证券之星消息，健康元05月08日在投资者关系平台上答复投资者关心的问题。我们理解广大投资者对公司创新药业务的重视和期待，目前公司已上市的创新药占整体业绩比例较小，因此暂未单独详细披露。未来，相信公司创新药陆续上市后，在创新药产品进入快速增长期或成为营收主力时，我们将考虑根据市场需求和监管政策，优化信息披露内容，以便投资者更好地理解创新药对公司业绩的贡献。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025050800027957.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0046","BK0077","BK0114","BK1574","159992","06978","BK1161","600380","BK0028"],"gpt_icon":0},{"id":"2533190458","title":"健康元：目前在吸入制剂板块中仅有妥布霉素吸入溶液这一创新药品种","url":"https://stock-news.laohu8.com/highlight/detail?id=2533190458","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533190458?lang=zh_cn&edition=full","pubTime":"2025-05-08 18:21","pubTimestamp":1746699681,"startTime":"0","endTime":"0","summary":"证券之星消息，健康元05月08日在投资者关系平台上答复投资者关心的问题。目前，在公司的吸入制剂板块中，仅有妥布霉素吸入溶液这一创新药品种。未来，随着公司一系列创新药产品陆续获批上市，当创新药产品进入快速增长期，或者成为公司营收的主要贡献力量时，我们会充分考虑市场的实际需求以及监管政策的相关要求，对信息披露内容进行优化。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025050800027919.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","159992","600380","BK0028","BK0239","06978","BK1161","BK0046","BK0114","BK1574","BK0077"],"gpt_icon":0},{"id":"2533904310","title":"健康元：仿制药业务受集采政策影响，创新药管线处于研发阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2533904310","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533904310?lang=zh_cn&edition=full","pubTime":"2025-05-08 18:21","pubTimestamp":1746699680,"startTime":"0","endTime":"0","summary":"一方面，仿制药业务由于受到集采等政策因素的持续影响，面临较大压力。另一方面，公司的创新药管线目前主要处于研发阶段，从研发到成功上市并为公司贡献业绩，确实还需要一定的时间周期。后续，我们也会更多地披露创新药研发和上市的进展情况，希望您能给予我们更多的耐心和支持，与公司一同见证创新转型的成果。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025050800027916.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","BK0188","BK1574","06978","BK0046","600380","BK1161","BK0077","159992","BK0114"],"gpt_icon":0},{"id":"2533909490","title":"总投资4.75亿美元 阿斯利康无锡小分子药物新工厂正式开工","url":"https://stock-news.laohu8.com/highlight/detail?id=2533909490","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533909490?lang=zh_cn&edition=full","pubTime":"2025-05-08 18:13","pubTimestamp":1746699211,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK4588","BK4007","BK4568","159992","AZN","BK1574","BK4585","LU0109394709.USD","LU0889565916.HKD","LU1829250122.USD","LU0320765992.SGD","LU2236285917.USD","LU2417539215.USD","06978","LU2456880835.USD","BK1161","LU2462157665.USD"],"gpt_icon":0},{"id":"2533903671","title":"永泰生物-B05月08日主力净流出28.8万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2533903671","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533903671?lang=zh_cn&edition=full","pubTime":"2025-05-08 16:15","pubTimestamp":1746692137,"startTime":"0","endTime":"0","summary":"05月08日, 永泰生物-B股价跌1.86%，报收3.69元，成交金额117.7万元，换手率0.06%，振幅10.64%，量比2.66。永泰生物-B今日主力资金净流出28.8万元，上一交易日主力净流出0万元。该股近5个交易日下跌4.15%，主力资金累计净流出28.8万元；近20日主力资金累计净流出60.5万元，其中净流出天数为2日。该股主力净额占比0.02%，港股市场排名2428/2646。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508173626a6d77288&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508173626a6d77288&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","06978"],"gpt_icon":0},{"id":"2533916440","title":"永泰生物-B盘中异动 大幅上涨5.05%报3.950港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2533916440","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533916440?lang=zh_cn&edition=full","pubTime":"2025-05-08 09:36","pubTimestamp":1746668213,"startTime":"0","endTime":"0","summary":"2025年05月08日早盘09时36分，永泰生物-B股票出现异动，股价急速拉升5.05%。截至发稿，该股报3.950港元/股，成交量2000股，换手率0.00%，振幅0.00%。永泰生物-B股票所在的生物技术行业中，整体跌幅为0.04%。消息层面，截至09时36分，《永泰生物-B：2024年亏损1.87亿元》资讯为影响永泰生物-B的重要信息。该信息摘要如下：中证智能财讯永泰生物-B4月29日披露2024年度报告。以4月29日收盘价计算，永泰生物-B目前市净率约-138.34倍。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050809365497528b3f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050809365497528b3f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","06978","BK1161"],"gpt_icon":0},{"id":"2533622568","title":"涉及减肥药？股价盘中多次触及涨停 常山药业回应：艾本那肽无最新进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2533622568","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533622568?lang=zh_cn&edition=full","pubTime":"2025-05-07 15:16","pubTimestamp":1746602164,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1161","159992","BK0172","06978","BK1574","300255","BK0239","BK0070"],"gpt_icon":0},{"id":"2533462501","title":"创新药概念持续调整 百济神州跌7.31% 机构指医药板块中最值得关注的仍是创新药赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2533462501","media":"金吾资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533462501?lang=zh_cn&edition=full","pubTime":"2025-05-07 14:03","pubTimestamp":1746597782,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念持续调整，加科思 跌13.95%，百济神州跌7.31%，君实生物跌6.75%，荣昌生物跌6.6%，药明生物跌6.24%。国金证券研报指，医药板块中最值得关注的仍将是创新药赛道，该行认为对创新医药投资机会的把握将是贯穿2025年全年医药投资的主线，在当前时点重点看好创新药出海龙头和仿创结合龙头，同时积极关注会议数据发布和海外BD商务合作进程。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050714034194eedfd7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050714034194eedfd7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","LU0588546209.SGD","BK1588","06160","BK1515","BK1583","BK1500","LU0307460666.USD","LU1969619763.USD","LU2328871848.SGD","BK1574","09939","06978"],"gpt_icon":0},{"id":"2533623745","title":"A股创新药概念午后持续下挫，百济神州跌近9%，荣昌生物、益方生物、一品红、信立泰、迪哲医药等多股跌超5%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2533623745","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533623745?lang=zh_cn&edition=full","pubTime":"2025-05-07 13:56","pubTimestamp":1746597395,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1500","LU1064131003.USD","159982","BK1588","LU2148510915.USD","159992","BK1583","BK0188","BK0183","LU0307460666.USD","LU1969619763.USD","LU1064130708.USD","BK1574","LU0588546209.SGD","09995","300723","002294","688331","688192","ONC","BK0187","399300","BK0028","LU2328871848.SGD","BK1161","688235","06160","688382","06978","BK4139","BK0239","BK0196"],"gpt_icon":0},{"id":"2533253366","title":"【创新药概念持续调整 百济神州跌近9%】午后创新药概念持续下挫，百济神州跌近9%，荣昌生物、益方生物、一品红、信立泰、迪哲医药等多股跌逾5%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2533253366","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533253366?lang=zh_cn&edition=full","pubTime":"2025-05-07 13:54","pubTimestamp":1746597245,"startTime":"0","endTime":"0","summary":"午后创新药概念持续下挫，百济神州跌近9%，荣昌生物、益方生物、一品红、信立泰、迪哲医药等多股跌逾5%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/05/07135450187475.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK4139","159992","688192","LU2328871848.SGD","ONC","BK0239","LU0588546209.SGD","06978","BK0183","BK1588","688235","BK1500","002294","688331","LU0307460666.USD","BK0196","LU1969619763.USD","BK1583","BK0188","LU1064130708.USD","BK0028","09995","LU2148510915.USD","LU1064131003.USD","688382","300723","06160","BK0187","BK1161","BK1574"],"gpt_icon":0},{"id":"2533213691","title":"昌平区一季度GDP同比增长7.9%！民企助力跑赢全市增速","url":"https://stock-news.laohu8.com/highlight/detail?id=2533213691","media":"北京日报客户端","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533213691?lang=zh_cn&edition=full","pubTime":"2025-05-07 07:03","pubTimestamp":1746572580,"startTime":"0","endTime":"0","summary":"在民营企业的活力助推下，昌平区实现经济“开门红”，一季度地区生产总值同比增长7.9%，跑赢全市增速。创新安全电池接到储能大单先进能源是昌平区的三大主导产业之一，这一领域也成为民营企业创新热点。悉心培育下，民营经济正成为昌平区经济发展、科技创新的重要动力。2024年昌平区规模以上民营企业达2109家，占全区规模以上企业比重为79.8%，实现收入3494.3亿元，同比增长12.4%。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2025-05-07/doc-inevssqf3893232.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","BK1574","06978","09969","BK4213","GDP"],"gpt_icon":0},{"id":"2533850000","title":"重磅!远大医药(00512)全球创新药STC3141中国II期临床数据亮剑，脓毒症治疗迎来突破性进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2533850000","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533850000?lang=zh_cn&edition=full","pubTime":"2025-05-06 18:28","pubTimestamp":1746527318,"startTime":"0","endTime":"0","summary":"智通财经APP讯，近日，港股科技创新型国际化医药企业远大医药 传来一则重磅消息，公司自主研发的全球创新药物STC3141在中国开展的用于治疗脓毒症的II期临床研究成功达到临床终点，试验结果证实了STC3141在脓毒症治疗中的有效性和安全性，该临床研究进度处于全球脓毒症研究领域前列。后续，远大医药将积极与药监局展开深度沟通，申请突破性治疗药物资格，让STC3141尽早惠及广大脓毒症患者，填补临床空白。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1289702.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","159992","BK1574","00512","06978","BK1161"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.eaal.net","stockEarnings":[{"period":"1week","weight":-0.0937},{"period":"1month","weight":0.0056},{"period":"3month","weight":0.5565},{"period":"6month","weight":0.9889},{"period":"1year","weight":0.0948},{"period":"ytd","weight":0.5565}],"compareEarnings":[{"period":"1week","weight":0.0161},{"period":"1month","weight":0.1285},{"period":"3month","weight":0.0821},{"period":"6month","weight":0.1032},{"period":"1year","weight":0.2336},{"period":"ytd","weight":0.14}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"永泰生物制药有限公司是一家主要从事用于治疗癌症的细胞免疫产品的研发、制造及商业化业务的中国投资控股公司。其主要产品是EAL、CAR-T细胞系列及TCR-T细胞系列产品。EAL是一种多靶点细胞免疫治疗产品。它还提供细胞冻存服务。该公司主要在中国境内开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.065686},{"month":2,"riseRate":0.6,"avgChangeRate":0.206387},{"month":3,"riseRate":0.4,"avgChangeRate":-0.092735},{"month":4,"riseRate":0.2,"avgChangeRate":-0.078794},{"month":5,"riseRate":0.4,"avgChangeRate":-0.009848},{"month":6,"riseRate":1,"avgChangeRate":0.116747},{"month":7,"riseRate":0,"avgChangeRate":-0.121182},{"month":8,"riseRate":0.4,"avgChangeRate":-0.037653},{"month":9,"riseRate":0.2,"avgChangeRate":-0.026649},{"month":10,"riseRate":0.6,"avgChangeRate":0.001262},{"month":11,"riseRate":0.6,"avgChangeRate":0.007893},{"month":12,"riseRate":0.8,"avgChangeRate":0.087803}],"exchange":"SEHK","name":"永泰生物-B","nameEN":"IMMUNOTECH-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.4","shortVersion":"4.33.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"永泰生物-B,06978,永泰生物-B股票,永泰生物-B股票老虎,永泰生物-B股票老虎国际,永泰生物-B行情,永泰生物-B股票行情,永泰生物-B股价,永泰生物-B股市,永泰生物-B股票价格,永泰生物-B股票交易,永泰生物-B股票购买,永泰生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}